Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435542 | 0.78 | CYP3A4 (0.56) | KHKALDH1A1CYP3A4TRPV4CSNK1A1 | |
| SCHEMBL165074 | 0.78 | GPR35 (0.41) | KHKALDH1A1CYP3A4TRPV4CSNK1A1 | |
| SCHEMBL29421236 | 0.78 | GPR35 (0.41) | KHKALDH1A1CYP3A4TRPV4CSNK1A1 | |
| SCHEMBL30107963 | 0.78 | TRPV4 (0.38) | KHKALDH1A1TRPV4CYP11B2KDM4E | |
| SCHEMBL2652439 | 0.78 | ADRB2 (0.44) | KHKALDH1A1TRPV4CYP11B2ADRB2 | |
| SCHEMBL9844450 | 0.78 | TRPV4 (0.38) | KHKALDH1A1CYP3A4TRPV4CYP11B2 | |
| SCHEMBL7922013 | 0.78 | TRPV4 (0.38) | KHKALDH1A1TRPV4CYP11B2KDM4E | |
| SCHEMBL631036 | 0.78 | KHK (0.37) | KHKALDH1A1CYP3A4TRPV4CYP11B2 | |
| SCHEMBL11028824 | 0.77 | CYP3A4 (0.37) | KHKALDH1A1CYP3A4TRPV4CYP11B2 | |
| SCHEMBL1951099 | 0.77 | CYP3A4 (0.58) | ALDH1A1CYP3A4ADRB1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4141006-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| EP-4141006-A1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2022-12-20 | — | — | US | disclosed |
| EP-3529251-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| EP-3529251-B1 | NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| CN-109843887-B | Nalidinone derivatives and their use in the treatment of cardiac arrhythmias | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210284635-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2021-09-16 | — | — | US | disclosed |
| US-20210284635-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | NOVARTIS AG (CH) | 2021-09-16 | — | — | US | disclosed |
| US-10844055-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| EP-2640722-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | KHK 2129/4885ALDH1A1 1091/4885CYP3A4 73/4885 |
| US-20210284635-A1 | NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA | SCN1B, SCN3A, SCN5A | KHK 2973/4885ALDH1A1 1241/4885CYP3A4 407/4885 |
| US-10844055-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | KHK 2188/4885ALDH1A1 1493/4885CYP3A4 281/4885 |
| US-11530213-B2 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | SCN1B, NPR3, SCN3A | KHK 2188/4885ALDH1A1 1493/4885CYP3A4 281/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | KHK 3068/4885ALDH1A1 1372/4885CYP3A4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.